Sun Pharmaceutical Industries has entered into a Rs 240-crore global licensing deal with the Indian Institute of Chemical Technology, Hyderabad under the Council of Scientific and Industrial Research Indian (CSIR) for developing new drugs. The company said the agreement, in which Sun Pharma will get an exclusive global license for patents, is part of its broader strategy to enhance its global specialty pipeline. The deal includes patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma’s specialty focus areas, the Mumbai-based pharmaceuticals company said in a regulatory filing on Wednesday.
As part of the deal, the CSIR-Indian Institute of Chemical Technology (CSIR-IICT) will get upfront and milestone payments totaling up to Rs 240 crore, and royalties on net sales from commercialization of the products developed using these patents, Sun Pharma said.
Sun Pharma said it will be responsible for development, regulatory filings, manufacturing and commercialization of these potential products.
“This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline,” said Dilip Shanghvi, managing director, Sun Pharmaceutical Industries.
“CSIR-IICT is well-known for its high quality research and we are proud to be associated with them,” he added.
This agreement will facilitate addition of pre-clinical candidates to Sun Pharma’s global specialty pipeline.
A successful clinical development of these potential compounds may enable Sun Pharma to commercialize pharmaceutical products for various therapeutic indications over the long term.
Shares in Sun Pharma fell as much as 6.72 per cent during the session, before settling 4.69 per cent lower for the day at Rs 417.05 apiece on the BSE, underperforming the benchmark Sensex index which finished up 0.96 per cent.
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24×7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.
Source: NDTV Profit